+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Drug Device Combination Products Market Size, Share & Trends Analysis Report by Product (Transdermal Patches, Inhalers, Infusion Pumps, Drug Eluting Stents, Antimicrobial Catheters), and Segment Forecasts, 2022-2030

  • ID: 4582072
  • Report
  • April 2022
  • Region: Global
  • 105 Pages
  • Grand View Research

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan, plc
  • C.R. Bard, Inc.
  • Medtronic
  • Mylan N.V.
  • Novartis AG
The global drug device combination products market size is expected to reach USD 251.9 billion by 2030. It is expected to expand at a CAGR of 8.8% from 2022 to 2030. The rising demand for minimally invasive techniques due to enhanced patient outcomes associated with it is the high impact-rendering driver of this market. These devices facilitate early diagnosis and reduced treatment duration in a majority of surgical procedures. Growing demand is also a consequence of minimal pain, heightened cost efficiency, improved safety, better efficacy, rapid recovery, and reduced hospital stay rendered by these devices.



The increasing presence of regulatory healthcare authorities enforcing clearly defined protocols for premarket authorizations is anticipated to support manufacturers in gaining approvals for their products. Recently, the U.S. FDA incorporated the lean management process mapping approach to building a more cohesive, streamlined, systematic, and collaborative system for the review of the aforementioned products. Safety guidelines and recommendations issued by these authorities are presumed to increase the adoption of these products in the future and boost overall growth during the forecast period.

Severe side effects and drug interactions associated with therapeutics owing to drug absorption by unintended sites in the body are anticipated to induce the need for targeted therapy, thereby propelling demand for drug-device combinations. For instance, consistent administration of Levodopa results in long-term complications such as motor fluctuations, dyskinesias, severe metabolic changes, and neurotoxic effects. These aforementioned factors drive the clinical urgency to incorporate alternatives based on targeted therapy, as in the case of drug-device combination products.

Drug Device Combination Products Market Report Highlights

  • by product, transdermal patches held the dominant share in 2021 owing to the increasing demand for self-administration of drugs in diseases requiring long-term treatment.
  • The inhalers product segment is anticipated to exhibit a lucrative CAGR of 10.3% over the forecast period owing to the rising prevalence of chronic diseases.
  • North America held the largest revenue share of over 40.0% in 2021 owing to the extensive new product development activities conducted by prominent players across this region.
  • Asia Pacific is anticipated to grow at a lucrative rate over the coming years owing to the increasing healthcare spending and rising awareness levels of physicians pertaining to the benefits of these products.
  • Key market players are engaged in various strategies such as new product launches and distribution agreements to gain market penetration. For instance, in February 2016, Medtronic introduced the New Resolute Onyx drug-eluting stent, commercially available in different sizes in Europe, thereby enhancing the company’s current product offerings.
  • High operational cost, stringent regulatory framework, and capital requirements keep entry barriers at a higher level, owing to which, the threat of new entrants is expected to be low .


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Drug Device Combination Products Market

What is the estimated value of the Global Drug Device Combination Products Market?

The Global Drug Device Combination Products Market was estimated to be valued at $127.8 Billion in 2022.

What is the growth rate of the Global Drug Device Combination Products Market?

The growth rate of the Global Drug Device Combination Products Market is 8.8%, with an estimated value of $251.9 Billion by 2030.

What is the forecasted size of the Global Drug Device Combination Products Market?

The Global Drug Device Combination Products Market is estimated to be worth $251.9 Billion by 2030.

Who are the key companies in the Global Drug Device Combination Products Market?

Key companies in the Global Drug Device Combination Products Market include Abbott Laboratories, Terumo Corporation, Stryker Corporation, Mylan N.V., Medtronic, St. Jude Medical, Inc., Allergan, plc, Boston Scientific Corporation and Teleflex Incorporated.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan, plc
  • C.R. Bard, Inc.
  • Medtronic
  • Mylan N.V.
  • Novartis AG

Chapter 1 Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2 Executive SummaryChapter 3 Market Snapshot
Chapter 4 Market Variables, Trends & Scope
4.1. Market segmentation & scope
4.2. Market Driver Analysis
4.2.1. Increasing demand for minimally invasive drug delivery devices
4.2.2. Technological advancements
4.2.3. Growing popularity of point of care treatment
4.2.4. Consistent interventions by government healthcare organizations
4.2.5. Increasing awareness levels
4.2.6. Improving medical reimbursement framework
4.3. Market Restraint Analysis
4.3.1. High associated costs
4.3.2. Technical challenges in drug delivery
4.4. Penetration & Growth Prospect Mapping
4.5. Drug Device Combination-SWOT Analysis, by Factor (political & legal, economic and technological)
4.6. Industry Analysis-Porter's Five Forces
Chapter 5 Market Categorization 1: Product Estimates & Trend Analysis
5.1. Drug device combination market: Product Movement Analysis
5.2. Infusion Pumps
5.2.1. Infusion pumps market estimates and forecasts, 2018-2030 (USD Billion)
5.2.2. Volumetric
5.2.2.1. Volumetric market estimates and forecasts, 2018-2030 (USD Billion)
5.2.3. Disposable
5.2.3.1. Disposable market estimates and forecasts, 2018-2030 (USD Billion)
5.2.4. Syringe
5.2.4.1. Syringe market estimates and forecasts, 2018-2030 (USD Billion)
5.2.5. Ambulatory
5.2.5.1. Ambulatory market estimates and forecasts, 2018-2030 (USD Billion)
5.2.6. ImplanTable
5.2.6.1. ImplanTable market estimates and forecasts, 2018-2030 (USD Billion)
5.2.7. Insulin
5.2.7.1. Insulin market estimates and forecasts, 2018-2030 (USD Billion)
5.3. Orthopedic Combination Products
5.3.1. Orthopedic combination products market estimates and forecasts, 2018-2030 (USD Billion)
5.3.2. Bone graft implants
5.3.2.1. Bone graft implants market estimates and forecasts, 2018-2030 (USD Billion)
5.3.3. Antibiotic bone cement
5.3.3.1. Antibiotic bone cement market estimates and forecasts, 2018-2030 (USD Billion)
5.4. Photodynamic Therapy Devices
5.4.1. Photodynamic therapy devices market estimates and forecasts, 2018-2030 (USD Billion)
5.5. Transdermal Patches
5.5.1. Transdermal patches market estimates and forecasts, 2018-2030 (USD Billion)
5.6. Drug Eluting Stents
5.6.1. Drug eluting stents market estimates and forecasts, 2018-2030 (USD Billion)
5.6.2. Coronary stents
5.6.2.1. Coronary stents market estimates and forecasts, 2018-2030 (USD Billion)
5.6.2.2. Peripheral vascular stents market estimates and forecasts, 2018-2030 (USD Billion)
5.7. Wound Care Products
5.7.1. Wound care products market estimates and forecasts, 2018-2030 (USD Billion)
5.8. Inhalers
5.8.1. Inhalers market estimates and forecasts, 2018-2030 (USD Billion)
5.8.2. Dry powder
5.8.2.1. Dry powder market estimates and forecasts, 2018-2030 (USD Billion)
5.8.3. Nebulizers
5.8.3.1. Nebulizers market estimates and forecasts, 2018-2030 (USD Billion)
5.8.4. Metered dose
5.8.4.1. Metered dose market estimates and forecasts, 2018-2030 (USD Billion)
5.9. Antimicrobial Catheters
5.9.1. Antimicrobial catheters market estimates and forecasts, 2018-2030 (USD Billion)
5.9.2. Urological
5.9.2.1. Urological market estimates and forecasts, 2018-2030 (USD Billion)
5.9.3. Cardiovascular
5.9.3.1. Cardiovascular market estimates and forecasts, 2018-2030 (USD Billion)
5.9.4. Others
5.9.4.1. Others market estimates and forecasts, 2018-2030 (USD Billion)
5.10. Others
5.10.1. Others market estimates and forecasts, 2018-2030 (USD Billion)
Chapter 6 Market Categorization 4: Regional Estimates & Trend Analysis, by Product, Application & Test
6.1. Drug Device Combination Market Share by Region, 2021
6.2. North America
6.2.1. North America market estimates and forecasts, by product, 2018-2030 (USD Billion)
6.2.1.1. U.S. market estimates and forecasts
6.2.1.2. Canada market estimates and forecasts
6.3. Europe
6.3.1. Europe market estimates and forecasts, by product, 2018-2030 (USD Billion)
6.3.1.1. U.K. market estimates and forecasts
6.3.1.2. Germany market estimates and forecasts
6.4. Asia Pacific
6.4.1. Asia Pacific market estimates and forecasts, by product, 2018-2030 (USD Billion)
6.4.1.1. Japan market estimates and forecasts
6.4.1.2. China market estimates and forecasts
6.4.1.3. India market estimates and forecasts
6.5. Latin America
6.5.1. Latin America market estimates and forecasts, by product, 2018-2030 (USD Billion)
6.5.1.1. Brazil market estimates and forecasts
6.5.1.2. Mexico market estimates and forecasts
6.6. MEA
6.6.1. MEA market estimates and forecasts, by product, 2018-2030 (USD Billion)
6.6.1.1. South Africa market estimates and forecasts
Chapter 7 Competitive Landscape
7.1. Strategy framework
7.2. Market participation categorization
7.3. Company Profiles
7.3.1. Abbott Laboratories
7.3.1.1. Company overview
7.3.1.2. Financial performance
7.3.1.3. Product benchmarking
7.3.1.4. Strategic initiatives
7.3.2. Terumo Corporation
7.3.2.1. Company overview
7.3.2.2. Financial performance
7.3.2.3. Product benchmarking
7.3.2.4. Strategic initiatives
7.3.3. Stryker Corporation
7.3.3.1. Company overview
7.3.3.2. Financial performance
7.3.3.3. Product benchmarking
7.3.3.4. Strategic initiatives
7.3.4. Mylan N.V.
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Medtronic
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. St. Jude Medical, Inc.
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Allergan, Plc
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Boston Scientific Corporation
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Novartis AG
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Teleflex Incorporated
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. C.R. Bard, Inc.
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. W.L.Core & Associates, Inc.
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Terumo Corporation
  • Stryker Corporation
  • Mylan N.V.
  • Medtronic
  • St. Jude Medical, Inc.
  • Allergan, plc
  • Boston Scientific Corporation
  • Novartis AG
  • Teleflex Incorporated
  • C.R. Bard, Inc.
  • W.L.Core & Associates, Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...